🟢 Kailera Therapeutics is trading 8.1% up in pre-market after August 12 report details obesity-pipeline progress

Kailera Therapeutics is trading at $20.01 (+8.1%) in pre-market after its August 12, 2026 second-quarter report outlined obesity-pipeline progress.

• The company reported approximately $1.17 billion in cash.
• Its oral ribupatide program has an active U.S. FDA IND; global Phase 3 obesity trials are planned for the first half of 2027.
• No separate August 18 company announcement was identified; broader markets are weaker, so the move appears primarily company-specific.